What are targeted therapies for lung cancer? 

Targeted therapies represent a specialised approach to cancer treatment that focuses on specific proteins or genetic mutations found within cancerous cells. Unlike traditional methods that affect all fast-growing cells, these treatments are designed to interfere with the specific signals that allow cancer to survive and multiply. In the United Kingdom, these therapies are becoming an increasingly important part of the clinical pathway for many patients, offering a more tailored management option based on the unique molecular profile of their condition. 

What We’ll Discuss in This Article 

• The definition and biological mechanism of targeted lung cancer therapies. 

• How healthcare professionals determine eligibility through biomarker testing. 

• The specific genetic mutations these drugs are designed to target. 

• The differences between targeted therapy and traditional chemotherapy. 

• Common side effects and how they are monitored by clinical teams. 

• The availability of these treatments within the NHS and NICE frameworks. 

Understanding the Nature of Targeted Therapy 

Targeted therapies are medicines designed to slow the spread of advanced non-small cell lung cancer by attacking the specific factors that help tumours grow. Targeted therapies (also known as biological therapies) are medicines designed to slow the spread of advanced non-small cell lung cancer and are only suitable for people who have certain proteins in their cancerous cells. These drugs work by “targeting” the differences between cancer cells and normal cells, such as the signals that tell a cell to divide or the ability of a tumour to develop its own blood supply. Because they focus on specific molecular targets, they are often used as part of a personalised management plan. 

Eligibility and the Role of Biomarker Testing 

Before starting targeted therapy, a patient must undergo specialised tests on a sample of their tumour to identify if any targetable mutations are present. These tests, often referred to as biomarker or genomic testing, look for changes in the DNA of the cancer cells that drive the disease’s growth. If a specific “fault” is found, such as a mutation in the EGFR or ALK genes, the patient may be eligible for a drug designed to block that specific pathway. This ensures that the treatment is only given to those who are most likely to benefit from it. 

Common Types of Genetic Targets 

In the UK, several different genetic mutations have been identified that can be addressed with specific targeted therapy drugs. The most common targets include the Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK), both of which are primarily found in non-small cell lung cancers. A variety of licensed cytotoxic immunotherapies and biological targeted therapies for treating NSCLC are used, and NICE has published technology appraisals covering many of these for the NHS. 

• EGFR mutations: These are often treated with drugs called tyrosine kinase inhibitors (TKIs), which block the signals that tell the cancer cells to grow. 

• ALK rearrangements: Specific medications are used to inhibit the abnormal ALK protein that causes cells to multiply uncontrollably. 

• ROS1 and BRAF mutations: Other less common mutations can also be targeted with specialised oral medications or combinations. 

Comparison of Targeted Therapy and Chemotherapy 

Feature	Targeted Therapy	Traditional Chemotherapy
Primary Target	Specific proteins or genetic mutations	All rapidly dividing cells in the body
Administration	Mostly taken as daily tablets at home	Usually given as an intravenous drip in hospital
Side Effect Profile	More varied, often involving skin or digestion	Broadly includes nausea, hair loss, and fatigue
Eligibility	Requires specific biomarker test results	Broadly applicable to many cancer types

Managing Side Effects and Monitoring 

While targeted therapies are designed to be more precise, they can still cause side effects because the targeted proteins may also be present in some healthy tissues. Common side effects include skin rashes, diarrhoea, fatigue, and changes in liver function, which are monitored through regular blood tests and clinical reviews. Most patients are able to manage these symptoms with supportive care while continuing their daily lives. Your medical team will provide specific guidance on what to watch for and how to manage any discomfort that arises during the course of treatment. 

Conclusion 

Targeted therapies provide a precise way to manage certain types of lung cancer by focusing on the specific genetic drivers of the disease. By matching the right drug to the right mutation, healthcare teams can often achieve better control of the cancer with a different side effect profile than traditional chemotherapy. In the UK, these treatments are accessed through specialist oncology services following detailed biomarker testing. If you experience severe, sudden, or worsening symptoms, such as significant difficulty breathing or coughing up blood, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides an evidence-based overview of targeted therapies for lung cancer, intended for public education in the UK. The content was authored and reviewed by Dr. Stefan Petrov, a UK-trained physician with extensive experience in general medicine and emergency care. All information presented is strictly aligned with the clinical guidance and technology appraisals provided by the NHS and NICE.